• Regorafenib Reduces RRM2 in Melanoma

  2026-08-11

  The 2024 iScience study identifies RRM2 as a mechanistically important downstream mediator of Regorafenib activity in melanoma and connects RRM2 suppression with ERK/E2F3 signaling, reduced tumor-cell aggressiveness, and apoptosis. Its combination of viability, motility, RNA-sequencing, rescue, and in vivo experiments provides a useful framework for cancer biology research while leaving questions about direct molecular binding, biomarker selection, and clinical translation.

• Pepstatin A: Aspartic Protease Inhibitor Guide

  2026-08-10

  Pepstatin A is a pentapeptide aspartic protease inhibitor used to study pepsin, renin, HIV protease, and cathepsin D. Its strongest documented research value is as a mechanistic tool for enzyme assays, viral protein processing research, and osteoclast differentiation inhibition, with solvent and assay-context limits that require explicit controls.

• Ceftolozane Sulfate Research Workflows

  2026-08-09

  Build reproducible susceptibility, time-kill, and PK/PD experiments around the PBP3-focused activity of Ceftolozane sulfate. This guide separates direct compound effects from tazobactam-dependent coverage, helping researchers model Pseudomonas aeruginosa activity, resistance boundaries, and exposure-driven efficacy.

• Regorafenib Reduces RRM2 in Melanoma

  2026-08-08

  The 2024 iScience study identifies RRM2 as a downstream mediator of Regorafenib activity in melanoma and connects its suppression to ERK/E2F3 signaling. The findings extend the mechanistic rationale for using this multikinase inhibitor in melanoma research while highlighting the need for validation in immune-competent and clinical models.

• Exercise Capacity Before Muscle Dysfunction in PH

  2026-08-07

  Zhang et al. show that exercise intolerance emerges before measurable intrinsic skeletal muscle dysfunction in rat models of pulmonary hypertension, with right-ventricular and cardiopulmonary impairment preceding major changes in muscle structure or performance. The study’s strain- and severity-dependent design helps distinguish central limitations from peripheral muscle mechanisms in experimental PH.

• Oral Faropenem Sodium: AMR Risks and Research Implications

  2026-08-07

  This article examines the unique position of faropenem sodium as an oral penem antibiotic, focusing on its broad antimicrobial activity and the growing concern over antimicrobial resistance (AMR) linked to its increased use. The reviewed study underscores the urgent need for rational deployment in both clinical and research settings to limit cross-resistance and preserve carbapenem efficacy.

• hiPSC-Derived Intestinal Organoids Enable Advanced PK Modeli

  2026-08-06

  This study introduces an efficient protocol for generating human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) that exhibit mature drug-metabolizing activities. By providing a physiologically relevant in vitro model, the method offers substantial improvements for pharmacokinetic research, especially in predicting human drug absorption and metabolism.

• IGF2BP2 Inhibition Disrupts m6A-Driven Glycolysis in Ovarian

  2026-08-06

  This study identifies IGF2BP2 as a pivotal m6A reader promoting cell cycle progression and glycolytic metabolism in ovarian cancer. By integrating single-cell transcriptomics with functional genomics and metabolic assays, the research demonstrates that targeting IGF2BP2 impairs tumor cell proliferation and metabolic reprogramming, highlighting its promise as a precision therapeutic target.

• 0.4% Trypan Blue Solution: Reliable Cell Viability Measureme

  2026-08-05

  0.4% Trypan Blue Solution addresses the need for rapid, direct discrimination between viable and non-viable cells in cell culture and cytotoxicity assays. It is suitable for research workflows assessing cell membrane integrity, but should not be used for diagnostic or clinical purposes.

• Carrier-Free Triterpene Prodrug for Targeted OSCC Therapy

  2026-08-05

  This study introduces a carrier-free, self-assembled triterpene-based prodrug strategy for targeted chemotherapy of oral squamous cell carcinoma (OSCC). By leveraging reactive oxygen species (ROS)-responsive linkers and dual triterpene agents, the approach achieves synergistic tumor cell apoptosis and reduced systemic toxicity, providing a streamlined alternative to complex nanocarrier systems.

• Meropenem in Translational Research: Mechanistic Depth & Str

  2026-08-04

  This article provides translational researchers with a mechanistically-driven, evidence-based guide to deploying Meropenem—a β-lactam antibiotic carbapenem—in resistant infection models. It synthesizes biological rationale, protocol innovations, competitive context, and forward-looking strategies, referencing current resistance dynamics and comparative agents like ceftolozane/tazobactam to inform robust experimental design.

• Sodium Dicloxacillin Monohydrate: Translational Insights for

  2026-08-04

  Explore the unique translational pharmacology and advanced protocol design of sodium dicloxacillin monohydrate in Gram-positive bacterial infection research. This article delivers a practical synthesis of in vitro, in vivo, and PK/PD insights for researchers optimizing MSSA models.

• Intraarticular Resiniferatoxin for Osteoarthritis Pain Relie

  2026-08-03

  The reference study evaluates intraarticular resiniferatoxin (RTX) as a novel intervention for osteoarthritis (OA) pain, highlighting its potent TRPV1-mediated chemical inactivation of sensory neurons. Findings suggest RTX can deliver long-lasting analgesia with potential for improved safety and tissue outcomes, marking a significant advance over traditional OA pain management strategies.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathway Insig

  2026-08-03

  The reference study reevaluates the metabolic fate of sumatriptan, revealing that cytochrome P450 enzymes contribute to its N-demethylation in addition to the established monoamine oxidase A (MAO A) pathway. This nuanced characterization of metabolic routes has implications for understanding drug-drug interactions and the broader context of neuroactive compound metabolism.

• Z-VAD-FMK in Apoptosis Inhibition: Optimizing Experimental W

  2026-08-02

  Z-VAD-FMK stands out as a gold-standard pan-caspase inhibitor for dissecting apoptotic pathways and immune cell regulation, with robust performance in both in vitro and in vivo models. This guide delivers actionable protocol enhancements, troubleshooting strategies, and translational insights drawn from the latest reference study on host-pathogen interactions.

446 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page